hVIVO Regulatory News (HVO)

hVIVO plc

("hVIVO or the "Company")

Rule 2.9 Announcement

In accordance with Rule 2.9 of the City Code on takeovers and Mergers, the Company confirms that, as at the date of this announcement, it had 83,583,946 ordinary shares of 5 pence each in issue. The Company holds no ordinary shares in treasury. Accordingly, the total number of voting rights in hVIVO is 83,583,946. The International Securities Identification Number ("ISIN") for hVIVO's ordinary shares is GB00B6ZM0X53.

For further information please contact:

hVIVO plc +44 (0)20 7756 1300

Anesh Patel, Interim Finance Director and Company Secretary

Fleur Wood, EVP, Investor Relations & Communications

Numis Securities Limited (Nominated Adviser) +44 (0)20 7260 1000

Freddie Barnfield / Huw Jeremy

FTI Consulting (Financial PR) +44 (0)20 3727 100

Simon Conway / Victoria Foster Mitchell

Notes to Editors:

hVIVO plc is pioneering a human-based analytical platform to accelerate drug discovery and development in respiratory and infectious diseases. Leveraging human disease models in flu, RSV and asthma exacerbation, the hVIVO platform captures disease in motion, illuminating the entire disease life cycle from healthy to sick and back to health. Based in the UK, market leader hVIVO has conducted more than 50 clinical studies, inoculated over 2500 volunteers and has three first-in-class therapies currently in development.